Previous research has demonstrated the promise of using carbon monoxide (CO) as an anticancer therapeutic agent, with reactive oxygen species (ROS)-activated CO prodrugs representing a new targeted cancer treatment strategy. In the current study, researchers from Georgia State University presented the discovery and preclinical evaluation of novel ROS-activated metal-free CO prodrugs.
Novartis AG has divulged pyrazolopyrimidine derivatives acting as methylcytosine dioxygenase TET2 inhibitors and thus reported to be useful for the treatment of cancer.
Aria Pharmaceuticals Inc. has synthesized compounds acting as caspase-1 (IL-1β-converting enzyme) and pyroptosis inhibitors reported to be useful for the treatment of alopecia, autoimmune hemolytic anemia, chronic kidney disease, duodenal ulcer, hepatitis B, osteoarthritis, systemic lupus erythematosus and uveitis, among others.
West China Hospital of Sichuan University has disclosed piperidine derivatives acting as μ-opioid receptor agonists and sigma non-opioid intracellular receptor 1 (SIGMAR1) antagonists.
Sernova Corp. has announced that its hemophilia A program, combining the Sernova Cell Pouch with a patient’s own cells corrected for the production of factor VIII (FVIII), has been awarded U.S. orphan drug and rare pediatric disease designations.
Researchers from Seoul National University presented results of preclinical evaluation of a new TNF-α/OX40L bispecific antibody, IMB-101, being developed for the treatment of rheumatoid arthritis (RA).
Ethris GmbH has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with a first-in-human trial of its inhaled mRNA program, ETH-47, in healthy participants for the treatment and prophylaxis of respiratory viral infections.
RSS
